{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:24:22Z","timestamp":1781173462467,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12325-018-0793-y","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T10:57:55Z","timestamp":1538045875000},"page":"2015-2023","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors"],"prefix":"10.1007","volume":"35","author":[{"given":"Suresh K.","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando F.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev M.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"issue":"1","key":"793_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65\u201375. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(17)30909-9\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"19","key":"793_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/jco.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973\u201380. \n                    https:\/\/doi.org\/10.1200\/jco.2017.76.6840\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"8","key":"793_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.70.4320\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"22","key":"793_CR4","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood. 2017;130(22):2392\u2013400. \n                    https:\/\/doi.org\/10.1182\/blood-2017-06-788323\n                    \n                  .","journal-title":"Blood"},{"key":"793_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy256","author":"S Vos de","year":"2018","unstructured":"de Vos S, Swinnen LJ, Wang D, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study. Ann Oncol. 2018. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdy256\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"10","key":"793_CR6","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0313\n                    \n                  .","journal-title":"Cancer Discov"},{"issue":"4","key":"793_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/10428194.2017.1361024","volume":"59","author":"A Parikh","year":"2018","unstructured":"Parikh A, Gopalakrishnan S, Freise KJ, et al. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2018;59(4):871\u20139. \n                    https:\/\/doi.org\/10.1080\/10428194.2017.1361024\n                    \n                  .","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"793_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcph.821","volume":"57","author":"AH Salem","year":"2017","unstructured":"Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57(4):484\u201392. \n                    https:\/\/doi.org\/10.1002\/jcph.821\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"793_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/jcph.730","volume":"56","author":"SK Agarwal","year":"2016","unstructured":"Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin\u2019s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. 2016;56(11):1335\u201343. \n                    https:\/\/doi.org\/10.1002\/jcph.730\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"793_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","volume":"83","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017;83(4):846\u201354. \n                    https:\/\/doi.org\/10.1111\/bcp.13175\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"793_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-016-0485-9","volume":"37","author":"AH Salem","year":"2017","unstructured":"Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers. Clin Drug Investig. 2017;37(3):303\u20139. \n                    https:\/\/doi.org\/10.1007\/s40261-016-0485-9\n                    \n                  .","journal-title":"Clin Drug Investig"},{"issue":"6","key":"793_CR12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/jcph.858","volume":"57","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Shebley M, Salem AH. Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model. J Clin Pharmacol. 2017;57(6):796\u2013804. \n                    https:\/\/doi.org\/10.1002\/jcph.858\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"793_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359\u201367. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.003\n                    \n                  .","journal-title":"Clin Ther"},{"issue":"11","key":"793_CR14","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jcph.741","volume":"56","author":"AH Salem","year":"2016","unstructured":"Salem AH, Agarwal SK, Dunbar M, et al. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016;56(11):1355\u201361. \n                    https:\/\/doi.org\/10.1002\/jcph.741\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"793_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/dmd.116.071613","volume":"45","author":"H Liu","year":"2017","unstructured":"Liu H, Michmerhuizen MJ, Lao Y, et al. Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites. Drug Metab Dispos. 2017;45(3):294\u2013305. \n                    https:\/\/doi.org\/10.1124\/dmd.116.071613\n                    \n                  .","journal-title":"Drug Metab Dispos"},{"key":"793_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","volume":"74","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Hu B, Salem AH. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Eur J Clin Pharmacol. 2017;74:413\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"793_CR17","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/00498254.2017.1381779","volume":"48","author":"MS Chiney","year":"2018","unstructured":"Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica. 2018;48(9):904\u201310. \n                    https:\/\/doi.org\/10.1080\/00498254.2017.1381779\n                    \n                  .","journal-title":"Xenobiotica"},{"issue":"4","key":"793_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpdd.395","volume":"7","author":"TT Cheung","year":"2018","unstructured":"Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK. Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2018;7(4):435\u201340. \n                    https:\/\/doi.org\/10.1002\/cpdd.395\n                    \n                  .","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"793_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/cad.0000000000000522","volume":"28","author":"AH Salem","year":"2017","unstructured":"Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anticancer Drugs. 2017;28(8):911\u20134. \n                    https:\/\/doi.org\/10.1097\/cad.0000000000000522\n                    \n                  .","journal-title":"Anticancer Drugs"},{"issue":"4","key":"793_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00280-016-3144-1","volume":"78","author":"KJ Freise","year":"2016","unstructured":"Freise KJ, Dunbar M, Jones AK, et al. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemother Pharmacol. 2016;78(4):847\u201353. \n                    https:\/\/doi.org\/10.1007\/s00280-016-3144-1\n                    \n                  .","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"793_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hon.2373","volume":"35","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Menon RM, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol. 2017;35(4):679\u201384. \n                    https:\/\/doi.org\/10.1002\/hon.2373\n                    \n                  .","journal-title":"Hematol Oncol"},{"issue":"5","key":"793_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40262-016-0453-9","volume":"56","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Eckert D, et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet. 2017;56(5):515\u201323. \n                    https:\/\/doi.org\/10.1007\/s40262-016-0453-9\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"793_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/cpt.712","volume":"102","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH. Moving beyond maximum tolerated dose for targeted oncology drugs: use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients. Clin Pharmacol Ther. 2017;102(6):970\u20136. \n                    https:\/\/doi.org\/10.1002\/cpt.712\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"793_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0149-2918(01)80049-7","volume":"23","author":"S Gupta","year":"2001","unstructured":"Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther. 2001;23(3):451\u201366.","journal-title":"Clin Ther"},{"issue":"6","key":"793_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00228-007-0292-6","volume":"63","author":"H Dorani","year":"2007","unstructured":"Dorani H, Schutzer KM, Sarich TC, et al. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers. Eur J Clin Pharmacol. 2007;63(6):571\u201381. \n                    https:\/\/doi.org\/10.1007\/s00228-007-0292-6\n                    \n                  .","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"793_CR26","first-page":"213","volume":"46","author":"T Zimmermann","year":"1996","unstructured":"Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung. 1996;46(2):213\u20137.","journal-title":"Arzneimittelforschung"},{"key":"793_CR27","unstructured":"Venclexta (venetoclax tablets) [US prescribing information]. North Chicago: AbbVie Inc. 2016. Available from: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208573s000lbl.pdf"},{"issue":"1","key":"793_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1124\/dmd.112.048330","volume":"41","author":"H Kusuhara","year":"2013","unstructured":"Kusuhara H, Miura M, Yasui-Furukori N, et al. Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects. Drug Metab Dispos. 2013;41(1):206\u201313. \n                    https:\/\/doi.org\/10.1124\/dmd.112.048330\n                    \n                  .","journal-title":"Drug Metab Dispos"},{"key":"793_CR29","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9927-9","author":"AK Jones","year":"2016","unstructured":"Jones AK, Freise KJ, Agarwal S, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics, a selective BCL-2 inhibitor, in chronic lymphocytic leukemia and Non-Hodgkin\u2019s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016. \n                    https:\/\/doi.org\/10.1208\/s12248-016-9927-9\n                    \n                  .","journal-title":"AAPS J"},{"key":"793_CR30","unstructured":"Zithromax (azithromycin tablets and oral suspension) [US prescribing information]. New York: Pfizer, Inc. 2017. Available from: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050670s032,050710s046,050711s043,050784s030lbl.pdf"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0793-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0793-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0793-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:04:32Z","timestamp":1569542672000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0793-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0793-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"8 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}